Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03485963 · ClinicalTrials.gov registry record · Phase 1
HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals
A Phase 1 study of HIV Infections, sponsored by Catherine Bollard.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 3
- Study locations
NCT03485963 is a Phase 1 study of HIV Infections that has completed, run by Catherine Bollard. The registered enrollment target is 7 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03485963, a Phase 1 study of HIV Infections, has completed, sponsored by Catherine Bollard.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on antiretroviral therapy (ART).
Conditions Studied
Interventions
- BIOLOGICAL HST-NEETs
Study Locations (3)
District of Columbia
- Whitman Walker Health Research Department (Wwh) - Washington D.C.
- Children's National Hospital - Washington D.C.
- Children's National Medical Center and WHITMAN WALKER HEALTH RESEARCH DEPARTMENT (WWH) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03485963
The ClinicalTrials.gov registry entry for NCT03485963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The listed sponsor is Catherine Bollard, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HST-NEETs is the first listed.
NCT03485963 reports 3 study locations spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03485963 about?
NCT03485963 is a clinical study titled "HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals". This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on antiretroviral therapy (ART).
What is the current status of trial NCT03485963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-03-21. Estimated completion is 2022-06-21.
What conditions does trial NCT03485963 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT03485963?
The interventions under investigation include: HST-NEETs (BIOLOGICAL).
Who is sponsoring clinical trial NCT03485963?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03485963 being conducted?
This trial has 3 study locations across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.